• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
All
Options & Futures
Funds
IPO Subscription
Structured Products
Investment Wiki
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List

Nurix Therapeutics(NRIX.US)

Overview
News
Financials
© 2026 Longbridge|Disclaimer

Event Tracking

Dec10
Mizuho Securities Analyst Reiterates Buy Rating for Nurix Therapeutics
13:38
Dec8
Stifel Nicolaus Maintains Buy Rating on Nurix Therapeutics
13:32
Nurix Therapeutics Unveils Phase 1 Trial Data of Bexobrutideg at ASH Annual Meeting
13:07
Nov7
Oppenheimer Reiterates Buy Rating on Nurix Therapeutics
19:56
Nov4
Gil Blum gives Nurix Therapeutics' bexodeg a buy rating
10:16
Oct23
Nurix Therapeutics Maintained at Hold Rating
08:47

Schedules & Filings

Schedules
Filings
Oct9
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 7.894 M, Net Income -86.42 M, EPS -1.0268

Jul9
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 44.06 M, Net Income -43.46 M, EPS -0.5181

Apr8
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 18.45 M, Net Income -56.35 M, EPS -0.6743

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
ANPA
86.850
+258.88%
+62.650
NBY
19.160
+102.54%
+9.700
VLN
2.480
+58.97%
+0.920
GP
1.240
+51.04%
+0.419
ATGL
30.610
+46.96%
+9.781
OPAD
2.190
+44.08%
+0.670
VCIG
0.9601
+41.00%
+0.279
THH
29.470
+36.31%
+7.850
APLX
113.630
+35.44%
+29.730
ZNTL
3.740
+31.69%
+0.900
View More